Safety and Efficacy Study of T-Guard to Treat Steroid-resistant Acute GVHD
- Conditions
- Graft vs Host Disease
- Interventions
- Biological: T-Guard
- Registration Number
- NCT02027805
- Lead Sponsor
- Xenikos
- Brief Summary
In this study, a combination of two antibodies both conjugated to a cell-killing toxin (so-called immunotoxins) will be evaluated. The antibodies are directed against T-cell antigens 'cluster of differentiation 3 antigen' (CD3) and CD7. Previous in vitro studies have demonstrated that this particular immunotoxin-combination, named T-Guard, acts synergistically in eliminating T cells with a preference for killing activated T-cells. In a subsequent clinical pilot-study, T-Guard has generated encouraging results when applied as third-line therapy for patients suffering form steroid-resistant acute Graft-versus-Host Disease (GVHD). Extensive biological and clinical responses could be noted in the absence of severe acute toxicities. Building on these results, the current study aims at evaluating the safety and efficacy of T-Guard for treating steroid-resistant GVHD when administered in an earlier phase of the disease process, i.e. as second-line instead of as third-line therapy.
- Detailed Description
The experimental design is a bicentric non-controlled fixed-dose Phase I/II study. A total of 20 adult patients with acute steroid-resistant GVHD will be enrolled in a 12 months period. The treatment consists of a standard dose of 4 infusions T-Guard (4 mg/m2), given 48-hours apart over a 4-hour period. The intended follow-up period is 6 months.
The primary objective is to determine the efficacy of T-Guard, 4 weeks after the first infusion (Day 28), in inducing an objective clinical response in patients with acute GVHD refractory to standard first line corticosteroid therapy.
Secondary objectives are:
* To evaluate the overall safety and efficacy of T-Guard during the first 6 months after imitation of therapy;
* To determine the pharmacokinetic profile of T-Guard;
* To determine the immunogenicity of T-Guard.
Exploratory objectives are:
* To study the specificity and kinetics of the treatment-induced depletion and subsequent repopulation of lymphocyte subsets;
* To evaluate diagnostic and predictive GVHD biomarkers relative to treatment outcomes.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 20
- Patients suffering from acute GVHD which is staged Grade II-IV according to the modified Glucksberg Criteria and progressing after 3 days, or not improving after 7 days, of methylprednisolone at a dose of 2 mg/kg per day.
- Age ≥18 years.
- Patients or an impartial witness (in case the patient is capable to provide verbal consent but not capable to sign the informed consent) should have given written informed consent.
- Patients receiving concomitant investigational therapeutics for acute GVHD, including investigational agents used for GVHD prophylaxis, at the time of enrollment.
- Patients with signs or symptoms suggestive of chronic GVHD.
- Patients requiring mechanical ventilation, requiring vasopressor support, requiring hemodialysis, having serum creatinine > 266 µmol/l (> 3 mg/dl), or having a serum albumin level of 15 g/l or less.
- Patients having uncontrolled bacterial, viral or fungal infections, at the discretion of the investigator, at the start of therapy.
- Patients with current signs or symptoms of active intrapulmonary disease.
- Patients with known hypersensitivity to any of the components of the study drug.
- Female patients who are pregnant, breast feeding, or, if sexually active, unwilling to use effective birth control for the duration of the study.
- Male patients who are, if sexually active, unwilling to use effective birth control for 30 days after the last infusion.
- Patients participating in a clinical trial with another investigational product within 30 days prior to providing informed consent.
- Patients whose decision to participate might be unduly influenced by perceived expectation of gain or harm by participation, such as patients in detention due to official or legal order.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description T-Guard T-Guard Four doses of T-Guard (4 mg/m2), administered at 48-hour intervals as 4 hour infusions.
- Primary Outcome Measures
Name Time Method Acute GVHD response rate Day 28 The acute GVHD response rate at 4 weeks after the first injection of T-Guard (Day 28), being defined as as the fraction of patients showing a complete or partial response (CR or PR)
- Secondary Outcome Measures
Name Time Method Anti-drug-antibodies Pre-treatment, Day 14, Day 28, Day 90, and Day 180 The occurrence and extent of humoral responses against T-Guard (anti-drug-antibodies, ADA).
Safety and tolerability of T-Guard During 6 months after initiation of treatment The safety and tolerability of T-Guard as assessed by evaluating Dose Limiting Toxicities (DLT's), adverse and serious adverse events reported during 6 months after initiation of treatment.
Incidence of chronic GVHD During 6 months after initiation of therapy Pharmacokinetic profile of T-Guard Up to Day 9 * Areas under the time-concentration curves (AUC);
* Peak concentration (Cmax);
* Time to peak concentration (Tmax);
* Terminal-phase elimination half-life (t1/2);
* Apparent Clearance (CL/F);
* Steady-state volume of distribution (Vss/F).Very good partial response rate Day 28 The proportion of patients achieving a very good partial response rate (VGPR) of their acute GVHD at 4 weeks after the first infusion (Day 28).
Acute GVHD relapse rate During 6 months after initiation of therapy Overall survival and progression free survival During 6 months after initiation of treatment The occurrence of treatment-induced cytokine release Day 1, 3, 5, and 7 The occurrence of treatment-induced cytokine release, as determined by measurement of interleukin-2 (IL-2), IL-4, IL-5, IL-6, IL-8, IL-10, tumor necrosis factor-alpha (TNF-a), and interferon-gamma (IFN-g) serum levels at t = 0 (pre-dose), 1 and 4 hours after starting of each infusion.
Trial Locations
- Locations (2)
Radboudumc
🇳🇱Nijmegen, Gelderland, Netherlands
University Hospital Münster
🇩🇪Münster, North Rhine-Westphalia, Germany